Immix Biopharma reports 95% CR rate in NEXICART-2; all MRD-negative patients convert to CR

Immix Biopharma, Inc.

All four MRD-negative relapsed/refractory AL Amyloidosis patients from ASH 2025 have converted to complete response (CR).
CR rate now 95% (19 of 20 patients) in Phase 2 NEXICART-2; no relapses observed in patients reaching CR.
All CRs reached within one year of follow-up post-dosing; median time to initial response was 7 days.
Phase 3 trial in newly diagnosed AL Amyloidosis planned to start in first half of 2027.
Next NEXICART-2 data update expected late September 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.